AgeX Therapeutics, Inc. (NYSE:AGE)
Industry: Financial

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of cellular and regenerative therapeutics for diseases of old age in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders. The company was founded in 2017 and is based in Alameda, California.

Current Quote*
Last: $1.240
Change: -0.040
Book: $12.174
Volume: 9,929

As Of: 02/25 13:02 ET
*Quotes delayed by 20min.

Graphs for AGE


3 Month Graph


6 Month Graph


1 Year Graph